title: Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year.
abstract: BACKGROUND
  The present study compared the effects of adjuvant bevacizumab and 5-fluorouracil on the efficacy and safety of trabeculectomy.
  
  
  METHODS
  A nonrandomized, prospective, interventional case study.
  
  
  METHODS
  A total of 62 patients in two groups undergoing primary trabeculectomy.
  
  
  METHODS
  In Group 1 (21 primary open-angle glaucoma, nine pseudoexfoliative glaucoma), trabeculectomy was performed with an adjuvant 5% solution of 5-fluorouracil administered for 4 min, intraoperatively. In Group 2 (21 primary open-angle glaucoma, 11 pseudoexfoliative glaucoma), trabeculectomy was enhanced with 1.25 mg of bevacizumab applied subconjunctivally immediately before and after surgery and again 1 and 7 days after surgery.
  
  
  METHODS
  Intraocular pressure, best corrected visual acuity, visual field index, bleb morphology, cornel endothelial cell count.
  
  
  RESULTS
  Mean intraocular pressure was 28.0 ± 8.0 mmHg before 5-fluorouracil-augmented trabeculectomy and 27.8 ± 9.5 mmHg before bevacizumab-augmented trabeculectomy. After 12 months, mean intraocular pressure was 13.6 ± 4.4 mmHg in the 5-fluorouracil group and 14.7 ± 4.7 mmHg in the bevacizumab group. A 30% reduction of initial intraocular pressure was attained in 86.7% of patients in the 5-fluorouracil group and 78.1% of patients in the bevacizumab group at the end of follow up. No significant differences were noted between the two studied groups with respect to corneal endothelial density, visual field indices and postoperative complications.
  
  
  CONCLUSIONS
  The 12-month intraocular pressure results showed no significant differences between the two groups of patients after bevacizumab or 5-fluorouracil to augment trabeculectomy. However, to obtain successful intraocular pressure control more patients in bevacizumab group needed medical therapy.
authors.affiliation: Department of Ophthalmology, Medical University, Lublin, Poland.
authors.forename: Justyna
authors.initials: J
authors.lastname: Jurkowska-Dudzińska
authors.forename: Ewa
authors.initials: E
authors.lastname: Kosior-Jarecka
authors.forename: Tomasz
authors.initials: T
authors.lastname: Zarnowski
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000963:Antimetabolites / Q000008:administration & dosage*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003228:Conjunctiva / Q000187:drug effects; D017889:Exfoliation Syndrome / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D056965:Injections, Intraocular; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D011446:Prospective Studies; D014065:Tonometry, Ocular; D014130:Trabeculectomy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000963:Antimetabolites; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D005472:Fluorouracil